Summary
The effect of verapamil and felodipine on imipramine-induced cardiac toxicity was assessed in anaesthetized rats. Rats received either infusion of saline (n = 13), or nonhypotensive doses of felodipine (n = 36) or verapamil (n = 36) over 40 minutes. In saline-pretreated rats IV bolus injection of imipramine (10 mg/kg) resulted in severe hypotension, bradycardia, electromechanical dissociation, and death within 3 minutes. Rats pretreated with nonhypotensive doses of felodipine (1, 3, 6, and 10 μg/kg/min) or verapamil (10, 30, 100, and 300 μg/kg/min) survived throughout the experiment, despite an initial fall in blood pressure within the first 5 minutes after imipramine administration. Blood pressure returned to baseline levels within 15 minutes. Intermittent ECG monitoring showed significant prolongation of QRS duration after imipramine in both saline (by 138%) and verapamil-pretreated rats (by 63%), whereas in the rats pretreated with felodipine no prolongation was observed ( + 3%). We conclude that, in our experimental model, felodipine, more than verapamil, protects against the cardiac effects of imipramine intoxication.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marchai JB, Forker AD. Cardiovascular effects of tricyclic antidepressant drugs: Therapeutic usage, overdose, and management of complications.Am Heart J 1982;103:401–414.
Nieman JT, Bessen HA, Rothstein RJ, Laks MM. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity.Am J Cardiol 1986;57:1154–1159.
Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants.N Engl J Med 1985;313:474–479.
Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman GA, Goodman LS, Rail TW, Murad F, eds.Goodman and Gilman’s The pharmacological basis of therapeutics. New York: MacMillan Publishing, 1985: 413–422.
Rudorfer MV, Potter WZ. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the “newer”versus the “older” drugs.Drugs 1989;37:713–738.
Merigian KS, Hedges JR, Kaplan LA, et al. Plasma catecholamines in cyclic antidepressant overdose.Ann Emerg Med 1988;17:403.
Wong RKS, Prince DA. Dendritic mechanisms underlying penicillin-induced epileptiform activity.Science 1979;204: 1228–1231.
Witte OW, Speckmann E, Waiden J. Motor cortical epileptic foci in vivo: Actions of a calcium channel blocker on paroxysmal neuronal depolarizations.Electroenceph Clin Neurophysiol 1987;66:43–55.
Eikenburg DC, Lokhandwala MF. Calcium antagonists and sympathetic neuroeffector function.J Auton Pharmac 1986;6:237–255.
Trouvé R, Nahas G. Ca2+ modulators as antidotes to imipramine and neurotransmitter toxicity.Proc Soc Exp Biol Med 1987;185:498–503.
Boström SL, Ljung B, Mardh S, et al. Interaction of the antihypertensive drug felodipine with calmodulin.Nature 1981;292:777–778.
Frommer DA, Kulig KW, Marx AJ, Rumack B. Tricyclic antidepressant overdose.JAMA 1987;257:521–526.
Kantor SJ, Glassman AH, Bigger JT, et al. The cardiac effects of therapeutic plasma concentrations of imipramine.Am J Psych 1978;135:213–219.
Cauvin C, Loutzenhiser R, Van Breemen C. Mechanisms of calcium antagonist-induced vasodilation.Ann Rev Pharmacol Toxicol 1983;23:373–396.
Cheung WY. Calmodulin plays a pivotal role in cellular regulation.Science 1980;207:19–27.
Choi DW. Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage.Trends Neurol Sci 1988;10:465–469.
Orrenius S, McConkey DJ, Bellomo J, Nicotera P. Role of Ca2+ in toxic cell killing.Trends Pharmacol Sci 1989;10: 281–285.
Eisner DA. The role of intracellular Ca ions in the therapeutic and toxic effects of cardiac glycosides and catecholamines.J Cardiovasc Pharmacol 1986;8:S2-S9.
Neiman CJ. The effects of isoprenaline on Ca2+-dependent oscillations in sheep cardiac Purkinje fibres.J Physiol 1987; 392:451–461.
Sheffield LT. Exercise stress testing. In: Braunwald E, ed.Heart disease. A textbook of cardiovascular medicine. Philadelphia: W.B. Saunders, 1987:253–277.
Opie LH. Calcium channel antagonists part II: Use of comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.Cardiovasc Drugs Ther 1988;1:461–491.
Hopkins RJ, Hill TWK. Effects of felodipine on red blood cell deformability.Drugs 1985;29(Suppl 2):42–44.
Godfraind T. Basic mechanisms and classification of calcium entry blockers. In: Godfraind T, Herman AG, Wellens D, eds.Calcium entry blockers in cardiovascular and cerebral & dysfunctions. The Hague: Martinus Nijhoff Publishers, 1984:9–36.
Godfraind T, Govoni S. Increasing complexity revealed in regulation of Ca2+ antagonist receptor.Trends Pharmacol Sci 1989;10:297–301.
Ganong WF. The general and cellular basis of medical physiology. In: Ganong WF, ed.Review of medical physiology. East Norwalk, CT: Prentice-Hall, 1987:1–37.
Lamers JM. The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin.Mol Cell Biochem 1987;78:169–176.
Johnson JD, Andrews CT, Khabbaza EJ, Mills JS. The interaction of felodipine with calcium-binding proteins.J Cardiovasc Pharmacol 1987;10:S53-S59.
Hofmann HP, Raschack M, Unger L. (S)-Emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders.Arzneim-Forsch 1989;39:304–308.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schoors, D.F., Reynaert, H., Huyghens, L. et al. Protective effects of felodipine and verapamil against imipramine-induced lethal cardiac conduction disturbances in the anaesthetized rat. Cardiovasc Drug Ther 5, 489–494 (1991). https://doi.org/10.1007/BF03029774
Issue Date:
DOI: https://doi.org/10.1007/BF03029774